行情

GNCA

GNCA

Genocea
NASDAQ

实时行情|Nasdaq Last Sale

2.250
+0.010
+0.45%
休市 16:00 11/15 EST
开盘
2.300
昨收
2.240
最高
2.350
最低
2.180
成交量
24.15万
成交额
--
52周最高
11.28
52周最低
1.990
市值
7,059.83万
市盈率(TTM)
-1.1856
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GNCA 新闻

  • Benzinga's Top Upgrades, Downgrades For November 15, 2019
  • Benzinga.1天前
  • Stifel likes Illumina in premarket analyst action
  • Seeking Alpha - Article.1天前
  • SVB Leerink Initiates Coverage On Genocea Biosciences with Outperform Rating
  • Benzinga.1天前
  • Genocea to Present at the Stifel 2019 Healthcare Conference
  • GlobeNewswire.2天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

GNCA 简况

Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.
展开

Webull提供Genocea Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。